Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Opus Genetics, Inc.NASDAQ: IRD
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity turns negative
Q1 FY2026 total equity was -$45.84M, compared with $5.07M a year earlier. Over 3 fiscal years it compounded at -30.8% a year.
Context
- Total equity amounted to 68.6% of total assets at the end of Q1 FY2026, up 58.1 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -1003.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 15.35M USD
- Year-over-year change
- +128.3%
- 4-year CAGR
- -8.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.35M | +128.3% |
| FY2024 | 2024-12-31 | 6.72M | -86.5% |
| FY2023 | 2023-12-31 | 49.91M | +7.9% |
| FY2022 | 2022-12-31 | 46.24M | +108.1% |
| FY2021 | 2021-12-31 | 22.22M | — |
Total Equity vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 total equity of -$45.84M is the 9th highest of the 10 companies compared; the peer median is $26.5M.
- Its year-over-year change of -1003.5% is the lowest of 10, against a peer median of -23.6%.
- Total equity amounts to 68.6% of total assets for IRD, versus a peer median of 65.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $241.48M | -22.4% | -16.6% | 88.7% | |
| Mar 2026 | $110.7M | -23.6% | -32.1% | 55.2% | |
| Mar 2026 | $87.48M | -43.8% | -28.0% | 65.5% | |
| Mar 2026 | $29.91M | +143.8% | -5.2% | 82.8% | |
| Mar 2026 | $26.5M | -47.5% | +60.1% | 22.5% | |
| Mar 2026 | $23.19M | +135.3% | +19.4% | 78.1% | |
| Mar 2026 | $10.38M | -89.0% | -47.7% | 4.3% | |
| Mar 2026 | $6.07M | -88.2% | -52.3% | 12.2% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$45.84M | -1003.5% | -30.8% | 68.6% |
| Mar 2026 | -$227.98M | +29.3% | — | 122.3% | |
| Peer median (excluding IRD) | $26.5M | -23.6% | -22.3% | 65.5% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.